Study of visual recovery after early oral high-dose corticosteroids in acute optic neuritis

Session Details

Session Title: Presented Poster Session: New & Interesting II

Venue: Poster Village: Pod 3

First Author: : M.Lefebvre FRANCE

Co Author(s): :    F. Mouriaux   C. Laurent   C. Doudnikoff   E. Boureaux              

Abstract Details

Purpose:

High doses of corticosteroid is the only validated treatment in the management of optic neuritis (ON). However, there is no evidence that early treatment is more effective on visual recovery.

Setting:

The objective of our study is to evaluate the interest of an early treatment by oral high-dose methylprednisolone, on visual recovery in ON.

Methods:

We did this retrospective, comparative study in Rennes’ hospital. We enrolled patients aged 18-52 years with idiopathic or in a context of multiple sclerosis optic neuritis. We assigned patients in two groups: those treated before or at 4 days of the beginning of symptoms and those treated between 5 and 15 days. The visual function was measured by the ETDRS visual acuity, the 30.2 automatic visual field, the contrast sensitivity, optical coherence tomography of the ganglion cells and optic nerve and visual evoked potentials. The primary endpoints was the visual acuity at 3 months.

Results:

Between September 2014 and October 2018 we screened 60 patients and enrolled 46. 17 patients were treated early (at or before four days) and 29 were treated between 5 and 15 days. We observed a rapid improvement in all parameters of visual function after oral high-dose of corticosteroids. However there was no significant difference on the visual acuity whether the treatment was given early or not. There were no difference either, on any others parameters (OCT of the ganglion cells and RNFL, visual evoked potentials, automatic visual field and the contrast sensitivity).

Conclusions:

This study shows that treatment’s delay for NOI breakthroughs have no impact on visual recovery of patients with idiopathic NOI or in a context of multiple sclerosis.

Financial Disclosure:

None